Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Esophagitis and CYP2C19[original query] |
---|
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. Journal of gastroenterology and hepatology 2006 Sep 21 (9): 1428-34. Ariizumi Ken, Ohara Shuichi, Koike Tomoyuki, Inomata Yoshifumi, Iijima Katsunori, Sekine Hitoshi, Noguchi Mitsunori, Sugiyama Koichi, Eda Yoshiki, Kayaba Shoichi, Kawamura Msashi, Shimosegawa Too |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. Journal of gastroenterology and hepatology 2007 Aug 22 (8): 1286-92. Lee Yi-Chia, Lin Jaw-Town, Wang Hsiu-Po, Chiu Han-Mo, Wu Ming-Shia |
Efficacy of a Low-Dose Omeprazole-Based Triple-Therapy Regimen for Helicobacter pylori Eradication Independent of Cytochrome P450 Genotype : The Japanese MACH Study. Clinical drug investigation 2005 25 (5): 293-305. Kuwayama Hajime, Luk Gordon, Yoshida Shunichi, Nakamura Takefumi, Kubo Mitsuhiko, Uemura Naomi, Harasawa Shigeru, Kaise Mitsuru, Sanuki Eiko, Haruma Ken, Inoue Masaki, Shimatani Tomohiko, Mieno Hiroshi, Kawanishi Masahiro, Watanabe Hidenobu, Nakashima Mituyoshi, Nakazawa Sabu |
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. Journal of gastroenterology and hepatology 2007 Feb 22 (2): 222-6. Kawamura Masashi, Ohara Shuichi, Koike Tomoyuki, Iijima Katsunori, Suzuki Hitoshi, Kayaba Shoichi, Noguchi Kenji, Abe Shinya, Noguchi Mitsunori, Shimosegawa To |
Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepato-gastroenterology 0 56 (91-92): 703-6. Saitoh Toshihito, Otsuka Hiroko, Kawasaki Takahiro, Endo Hitoshi, Iga Daijirou, Tomimatsu Masahiko, Fukushima Yasushi, Katsube Takao, Ogawa Kenji, Otsuka Kunia |
A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes. Journal of clinical gastroenterology 0 43 (10): 920-5. Tseng Ping-Huei, Lee Yi-Chia, Chiu Han-Mo, Wang Hsiu-Po, Lin Jaw-Town, Wu Ming-Shia |
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. The American journal of gastroenterology 2010 May 105 (5): 1046-52. Chen Wei-Ying, Chang Wei-Lun, Tsai Yu-Ching, Cheng Hsiu-Chi, Lu Cheng-Chan, Sheu Bor-Shya |
Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Archives of Iranian medicine 2010 Sep 13 (5): 406-12. Zendehdel Nader, Biramijamal Firouzeh, Hossein-Nezhad Arash, Zendehdel Nasrin, Sarie Hamidreza, Doughaiemoghaddam Masoud, Pourshams Akr |
CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D. Journal of gastroenterology and hepatology 2012 Jan 27 (1): 104-9. Sheu Bor-Shyang, Cheng Hsiu-Chi, Yeh Yi-Chun, Chang Wei-L |
Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China. BMC medical genetics 2015 16 15. Peng Xian-E, Chen Hua-Fang, Hu Zhi-Jian, Shi Xi-Sh |
Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis. The Kaohsiung journal of medical sciences 2015 May 31 (5): 255-9. Hsu Wen-Hung, Kuo Fu-Chen, Hu Huang-Ming, Hsu Ping-I, Wu Deng-Chyang, Kuo Chao-Hu |
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Current therapeutic research, clinical and experimental 2018 7 88 26-34. Kinoshita Yoshikazu, Kusano Motoyasu, Iwakiri Katsuhiko, Fujishiro Mitsuhiro, Tachikawa Naoto, Haruma K |
CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis. Journal of pediatric gastroenterology and nutrition 2019 Sep . Mougey Edward B, Williams Andre, Coyne Ashlan J Kunz, Gutiérrez-Junquera Carolina, Fernández-Fernández Sonia, Cilleruelo Maria Luz, Rayo Ana, Echeverría Luis, Román Enriqueta, González Lois Carmen, Chao Montserrat, Al-Atrash Hadeel, Lima John J, Franciosi James |
Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2021 Aug e14217. Yasuda Jessica L, Staffa Steven J, Nurko Samuel, Kane Madeline, Wall Stephanie, Mougey Edward B, Franciosi James P, Manfredi Michael A, Rosen Rach |
A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps. Pharmacogenomics and personalized medicine 2023 6 16 645-664. Eda Eken, David S Estores, Emily J Cicali, Kristin K Wiisanen, Julie A Johns |
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes. Archives of pharmacal research 2023 12 . Chang-Keun Cho, Eunvin Ko, Ju Yeon Mo, Pureum Kang, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Ch |
Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis. International journal of molecular sciences 2024 4 25 (7): . Paula Soria-Chacartegui, Marcos Navares-Gómez, Francisca Molina-Jiménez, Emilio J Laserna-Mendieta, Laura Arias-González, Pedro Majano, Sergio Casabona, Alfredo J Lucendo, Francisco Abad-Santos, Cecilio Santander, Pablo Zubia |
- Page last reviewed:Feb 1, 2024
- Content source: